Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

, inappropriate blood vessels that can cause further vision loss and more serious complications.  Release of vascular endothelial growth factor (VEGF) contributes to increased vascular permeability in the eye and inappropriate new vessel growth.  It is believed that anti-VEGF treatment may help decrease vascular permeability and edema and prevent the inappropriate growth of new blood vessels in the retina in patients with CRVO.

About Diabetic Macular Edema (DME)DME is the most prevalent cause of moderate vision loss in patients with diabetes.  DME is a common complication of Diabetic Retinopathy (DR), a disease affecting the blood vessels of the retina.  Clinically significant DME is a leading cause of blindness in younger adults (under 50).  Clinically significant DME occurs when fluid leaks into the center of the macula, the light-sensitive part of the retina responsible for sharp, direct vision.  Fluid in the macula can cause severe vision loss or blindness.

Approximately 370,000 Americans currently suffer from clinically significant DME, with 95,000 new cases arising each year.  According to the American Diabetes Association, more than 18 million Americans currently suffer from diabetes, and many other people are at risk for developing diabetes.  With the incidence of diabetes steadily climbing, it is projected that up to 10 percent of all patients with diabetes will develop DME during their lifetime.

About VEGF Trap-EyeVEGF Trap-Eye is a fully human fusion protein, consisting of soluble VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  VEGF Trap-Eye is a specific and highly potent blocker of these growth factors.  VEGF Trap-Eye is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it has achieved ... recognizes Aspire for delivering outstanding customer service to customers in ... "Achieving exceptional results for our customers is core to ... CEO of Aspire. "We are pleased Cisco has recognized our ... are proud to be part of the Cisco channel." ...
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... DALLAS, June 23, 2011 , - ReportsnReports ... and,Combination Therapies , Report in its store ... Combination,Therapies , Report now! Search 75000+ ... , Pharmaceuticals Market Research Reports Report ...
... Inc., a privately held biotechnology company that develops immunotherapeutics ... announced that 1-year data from Protege, the Company,s Phase ... patients, will be presented at the American Diabetes Association,s ... June 28, 2011 at 9:10 a.m. PDT. ...
Cached Medicine Technology:ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 2ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 3ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 4MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28 2
(Date:8/1/2014)... The American Telemedicine Association (ATA) ... and Peter Welch (D-VT), for their latest actions ... Act of 2014, which improves telemedicine coverage in ... improve healthcare access and affordability using telecommunications technology," ... "These cost-saving provisions are critical to improve telehealth ...
(Date:8/1/2014)... Market Publishers Ltd announces that ... added to its catalogue. , Pharmaceutical ... Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics ... include, among others, increasing ageing population, rising incomes ... the pharma market in India is anticipated to ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although many parents ... many overlook a common choking hazard: food. Such ... wheeze and cough after eating a handful of nuts. ... not obvious if the coughing was related to his illness ... wasn,t a cold. A cashew had become lodged in his ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2
... CryoCor, Inc. (Nasdaq:,CRYO), a medical device company focused ... Jackman, M.D., joined the Company,s,Scientific Advisory Board., ... to our Scientific,Advisory Board," said Dr. Ed Brennan, ... key thought leader in the field of cardiac ...
... 4 IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... Singer, Chief Executive Officer, and,Jeffrey Taylor, President and Chief Operating ... the UBS Global Healthcare Services,Conference in New York, NY., ... Date: Monday, February 11, 2008 Time: ...
... 2008) The 2008 HSR Impact Award, presented today ... D.C., honored two decades or research that ultimately brought ... , Now in its third year, the AcademyHealth HSR ... of health services research on health policy or practice. ...
... executive team; Jerry Noyce announces ... ... HFIT) announced today that John Griffin has joined the,company as chief ... officer and Jerry Noyce has retired as vice,chairman. HealthFitness is a ...
... and other products reach $3.8 million; revenue increased 18% to $3.75 ... markets - Strong operating leverage shows in sequential quarter comparisons, ... ... quarter fiscal 2008, - Purchase of medical waste disposal facility ...
... Improve Pediatric Emergency Care ... -, ... reducing the high level of infant mortality in,the United States, announced today that ... five new hospital programs that,received grants in January 2008 totaling $500,000. R Baby ...
Cached Medicine News:Health News:Dr. Warren Jackman Joins CryoCor Scientific Advisory Board 2Health News:Dr. Warren Jackman Joins CryoCor Scientific Advisory Board 3Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Award recognizes 2 decades of research that led to the adoption of risk adjustment tools 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 3Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 2Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 3Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 4Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 5Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 6Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 7Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 8Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 9Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 10Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 11Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 12Health News:R Baby Foundation Raises $2.5 Million in First Year 2Health News:R Baby Foundation Raises $2.5 Million in First Year 3Health News:R Baby Foundation Raises $2.5 Million in First Year 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: